Combined modality therapy of rectal cancers

Area of Science:

• Oncology
• Gastroenterology
• Surgical Oncology

Background:

• Rectal cancer affects men and women equally, with incidence rising with age, often diagnosed at advanced stages.
• Current cancer management emphasizes organ preservation and quality of life without compromising survival.
• Recent advancements include improved radiation techniques, chemotherapy, and surgical procedures for rectal cancer treatment.

Purpose of the Study:

• To discuss indications for preoperative radiochemotherapy in rectal cancer.
• To detail treatment-related side effects, prognostic parameters, tumor response, and outcomes.
• To describe various irradiation settings and chemotherapy schedules for rectal cancer.

Main Methods:

• Review of current treatment modalities for rectal cancer, including radiation and chemotherapy.
• Analysis of preoperative chemoradiation therapy for advanced/unresectable rectal cancer.
• Comparison of preoperative versus postoperative chemoradiation therapy outcomes.

Main Results:

• Preoperative chemoradiation can downstage tumors, increasing the use of anal-rectal-sparing procedures.
• Preoperative chemoradiation is as safe and tolerable as standard postoperative treatment.
• Postoperative combined modality therapy has shown reduced local recurrence in primary resectable rectal cancer (Dukes C).

Conclusions:

• Preoperative chemoradiation is a viable option for advanced rectal cancer, enhancing organ preservation and quality of life.
• Further discussion on preoperative radiochemotherapy indications, side effects, and outcomes is warranted.
• Combined modality therapy, both pre- and post-operative, shows promise in improving rectal cancer management.